Skip to main content

MM-398-01-03-04

NCT03088813

MM-398-01-03-04

Associated Conditions

CancerLung Cancer

Principal Investigator

Sponsor

IPSEN Bioscience, Inc.

This study will take place in 2 parts (Part 1 and Part 2). The purpose of Part 1 is to find out what is the best dose of irinotecan liposome injection to be used in Part 2 of the study. Once the best dose is found, Part 1 will be closed to enrollment and Part 2 will open.The purpose of Part 2 is to see how effective and safe the study drug is at treating subjects with small cell lung cancer. This will be done by comparing the effects of the study drug with the effects of topotecan. Topotecan is approved for the treatment of small cell lung cancer.

This study is currently enrolling.


Interested in participating?

Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.